Actively Recruiting
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Led by Hunan Province Tumor Hospital · Updated on 2024-09-19
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
CONDITIONS
Official Title
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Imaging diagnosis of extensive stage small-cell lung cancer
- Failed first-line EC plus PD-L1 treatment
- Performance status (PS) of 0 to 1
You will not qualify if you...
- Diagnosis of non-small cell lung cancer
- Women who are pregnant
- Patients with symptomatic brain metastases
- Performance status (PS) of 2 or higher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
N
Nong Yang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here